CA IX-directed immunoliposomes utilize a CA IX-specific antibody conjugated to a liposome carrier of an anti-cancer therapeutic that, upon binding of the antibody region to CA IX, can be taken up by the tumor cell. This evidence concerns the gene CA9 and cancer.